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Abstract
Rationale—Discerning cardiac myocyte cell cycle behavior is challenging owing to commingled 
cell types with higher proliferative activity.
Objective—To investigate cardiac myocyte cell cycle activity in development and the early 
postnatal period.
Methods and Results—To facilitate studies of cell type–specific proliferation, we have 
generated tissue-specific cell cycle indicator BAC transgenic mouse lines. Experiments using 
embryonic fibroblasts from CyclinA2-LacZ-floxed-EGFP, or CyclinA2-EGFP mice, demonstrated 
that CyclinA2-βgal and CyclinA2-EGFP were expressed from mid-G1 to mid-M phase. Using 
Troponin T-Cre;CyclinA2-LacZ-EGFP mice, we examined cardiac myocyte cell cycle activity 
during embryogenesis and in the early postnatal period. Our data demonstrated that right 
ventricular cardiac myocytes exhibited reduced cell cycle activity relative to left ventricular 
cardiac myocytes in the immediate perinatal period. Additionally, in contrast to a recent report, we 
could find no evidence to support a burst of cardiac myocyte cell cycle activity at postnatal day 15.
Conclusions—Our data highlight advantages of a cardiac myocyte–specific cell cycle reporter 
for studies of cardiac myocyte cell cycle regulation.
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Cell cycle regulation is a key factor in disease and regeneration. 1–4 Healing responses to 
injury often require cell cycle re-entry of tissue parenchyma and cognate vascular stro-mal 
fraction, comprising endothelial cells, vascular mural cells, and fibroblasts.1,3 Tissues that 
heal well in response to injury are able to replenish both tissue parenchymal cells and 
vascular stroma because of the ability of these cells to re-enter the cell cycle, or to be 
provided by tissue-resident stem cells.1,4,5 Some tissues, however, are composed of 
parenchymal cells that are refractory to cell cycle re-entry, and a major goal of regenerative 
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medicine is to understand factors regulating cell cycle within these cell types toward 
manipulations that may promote cell cycle re-entry. One such tissue is the heart, where adult 
cardiac myocytes are withdrawn from the cell cycle.6,7
Understanding cardiac myocyte cell cycle regulation lies at the heart of regenerative 
therapies for cardiac diseases and has been the subject of intensive study. One of the great 
challenges to this field is to clearly define the myocyte identity of proliferating cells.8 This is 
particularly challenging because myocytes comprise less than one half of all cell types 
within the heart9 and are closely intermingled with multiple other cell types of smaller size, 
including fibroblasts, pericytes, vascular smooth muscle cells, and endothelial cells.
Studies of cell cycle regulation can be facilitated by cell cycle reporter transgenes. Previous 
cell cycle reporter mice have been generated by in-frame fusion of fluorescent reporter 
transgenes to genes encoding protein fragments that are destabilized at discrete stages of the 
cell cycle.10 Initial iterations of this kind of reporter were generated using a cytomegalo-
virus-based enhancer, were subject to issues with transgene expression, and were not cell 
type–specific, although in more recent iterations, tissue conditional expression is 
possible.11,12 Investigation of cardiac myocyte proliferation with these reporters was 
recently reported.13 Here, we undertook a distinct approach and generated a CyclinA2-
reporter fusion protein under the control of the endogenous CyclinA2 locus. We adopted this 
strategy because CyclinA2 is an essential regulator of cell cycle expressed in all cycling cells 
from S to M phase,14 reasoning that this approach would give us a robust and sensitive 
reporter of cell cycle activity in any cell type of interest.
To facilitate studies of cell type–specific cell cycle behavior, we generated a BAC transgenic 
line, CyclinA2-lacZ-EGFP, that contained a transgene encoding a lacZ fusion in frame to the 
C-terminal coding sequence of cyclinA2. In these mice, the CyclinA2-lacZ fusion reporter is 
expressed under control of the cyclinA2 locus within BAC sequences and, on Cre-mediated 
excision, is converted to a cyclinA2-EGFP fusion gene, expressed under the control of the 
cyclinA2 locus only in the cell type that expressed Cre.
In this report, we demonstrate and characterize cell cycle–specific expression of cyclinA2-
lacZ and cyclinA2-EGFP fusion reporter transgenes and use this new tool, in concert with a 
cardiac myocyte–specific Cre, Troponin T (TnT)-Cre,15 to uncover unexpected findings 
concerning cardiac myocyte cell cycle regulation.
Methods
Transgenic Animals
All animals were maintained and experiments performed in accordance with institutional 
guidelines at University of California, San Diego. Protamine-Cre16 and TnT-Cre15 were 
purchased from Jackson Laboratories. CyclinA2-EGFP allele was produced by crossing 
CyclinA2-LacZ-EGFP with Protamine-Cre line. CyclinA2-LacZ-EGFP transgenics have 
been bred into a Black Swiss outbred background for >15 generations and has not exhibited 
gene silencing. Genotyping for transgene was performed by PCR, using following primers, 
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forward primer: 5′-CAGCCACAACGTCTATATCATGGC-3′, reverse primer: 5′-
TTGTCTGTGGCTATACCATC-3′, giving rise to 405bp amplicon.
Generation of BAC Transgenic Mice
BAC clone RP23-297G4 containing cyclinA2 was purchased from BACPAC Resources 
Center. BAC recombineering was performed with galK selection, and recombineering was 
performed as detailed (https://ncifrederick.cancer.gov/research/brb/protocol.aspx). After 
linearization with AscI, BAC DNA was purified by Sepharose column fractionation. DNA 
purity was examined by pulse field gel electrophoresis, and a fraction with highest purity 
was used for pronuclear injection.
Southern Blotting
Genomic DNA was purified from tail tip biopsies, followed by digestion with NcoI. 
Digested genomic DNA was separated by agarose gel electrophoresis. Short sequence of 
vector backbone adjacent to linearized AscI site was used as a probe (Figure 1A, pink bar). 
The probe was amplified by PCR using following primers, forward primer: 5′-
TAAAGTAGTGGTAATACTCCTGCTTAC-3′, reverse primer: 5′-
TCTATCTGCTACATAACTTACTT-3′.
Cell Culture and Cell Synchronization
Mouse embryonic fibroblasts (MEFs) were isolated by trypsinization of skin tissues of 
embryonic day 14.5 mouse embryos. MEFs were maintained in DMEM (Gibco), 10% fetal 
bovine serum at 37°C in 5% CO2. MEFs were synchronized in G0 phase by culturing in 
DMEM, 0.1% fetal bovine serum at 37°C in 5% CO2 for 72 hours.
Immunofluorescence
Embryos were fixed in 4% paraformaldehyde and embedded in Tissue-Tek OCT after 
sucrose gradient treatment. After denaturation with 1% SDS for 5 minutes, frozen sections 
were blocked with 10% donkey serum, 3% skim milk, 0.1% Triton, donkey anti-mouse IgG 
Fab fragment (715-007-003, Jackson Immunoresearch, 1:100), followed by incubation with 
following primary antibodies. Primary antibodies used for immunohistochemistry were anti-
TnT mouse monoclonal (13-11, Thermo Scientific, 1:200), anti-GFP rabbit polyclonal 
(ab290, Abcam, 1:400), anti-Serine28 phosphoHistone H3 rat monoclonal (HTA28, BD 
Pharmingen, 1:25), anti-Serine 10 phosphoHistone H3 rabbit polyclonal (06-570, Millipore, 
1:200), anti-α-actinin (Sarcomeric) mouse monoclonal (EA53, Sigma, 1:100), anti-
PDGFRα goat poly-clonal (AF1062, R&D Systems, 1:100), anti-CD31 rat monoclonal 
(ME13.3, BD Pharmingen, 1:50), anti-CD45 rat monoclonal (30-F11, eBioscience, 1:50), or 
anti-CD146 rat monoclonal (ME-9F1, BioLegend, 1:50). Secondary antibodies used were 
Alexa 488, 555, or 647 anti-rabbit, mouse, rat, or goat IgG (Life Technologies), followed by 
nuclear staining with DAPI. Stained sections were mounted with Dako fluorescence 
mounting medium and visualized using an Olympus confocal microscope (FV1000). 5-
Ethynyl-2′-deoxyuridine (EdU; 30 μg/g, dose per mouse body weight; Life Technologies) 
was injected 2 to 10.5 hours before dissection and detected with the Click-iT EdU Alexa 
Fluor 647 Imaging Kit (Life Technologies). EdU was intraperitoneally injected in pregnant 
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dams and adult mice or subcutaneously injected in the back of postnatal day (PN) 0 and PN1 
mice.
Quantitative Analysis
Quantitative analysis was performed using Image J software or Volocity software. To 
determine the number of myocardial nuclei of postnatal heart tissue sections, nuclei 
surrounded by staining with anti-PDGFRα, anti-CD31, anti-CD45, or anti-CD146 antibody 
were subtracted from total number of nuclei.
Results
Using BAC recombineering technology with galK selection,17 a BAC plasmid containing 
83.2 kbp upstream and 87.4 kbp downstream of the cyclin A2 transcription start site was 
engineered to insert a lacZ cassette flanked by loxP sites, followed by an EGFP cassette in 
frame immediately before the stop codon of cyclin A2 (Figure 1A). Thus, the cyclinA2-lacZ 
fusion gene would be expressed under control of the cyclin A2 locus as contained within 
BAC sequences. On Cre-mediated excision, CyclinA2-EGFP would be expressed under 
control of the cyclinA2 locus only in lineages that had expressed Cre (Figure 1B). After 
linearization, recombineered BAC DNA was injected into pronuclei (Online Figure IA). 
Southern blot screening confirmed 2 independent mouse lines (CyclinA2-lacZ-EGFP; 
Figure 1C).
To define phases of cell cycle in which CyclinA2-EGFP was expressed, a CyclinA2-EGFP 
mouse line was generated by germline ablation of the lacZ cassette in cyclinA2-lacZ-EGFP, 
using Protamine Cre.16 In this line, CyclinA2-EGFP should be expressed under control of 
the cyclinA2 locus within BAC sequences. MEFs were harvested from CyclinA2-EGFP 
embryos. MEFs were synchronized in G0 by serum starvation,18 then induced to re-enter 
cell cycle by addition of 10% fetal bovine serum in the presence of EdU (12 μM; Figure 
2A). Cultures were fixed with 4% paraformaldehyde every 6 hours, then immunostained 
with antibodies to GFP, the M phase–specific marker, Serine 28 phosphohistone 3,19 and 
stained for EdU, with DAPI nuclear staining. Attempts to visualize CyclinA2-EGFP 
expression by live imaging were not successful, for reasons which are not clear, but may be 
owing to low levels of transgene expression or quenching of EGFP within the context of the 
CyclinA2 fusion protein.
As shown in Figure 2B, MEFs initiated expression of CyclinA2-EGFP by 18 hours after 
serum induction (Figure 2B, c2), at mid-G1 when no cells yet demonstrated EdU 
incorporation (Figure 2B, c3). EdU incorporation, marking S phase, was evident by 24 hours 
after induction, and all cells marked by EdU were also positive for CyclinA2-EGFP (Figure 
2B, d2, d3). By 30 hours after induction, the M phase marker, Serine 28 phosphohistone 3, 
was observed (eg, in cells undergoing telophase as shown in Figure 2B, e4, yellow ellipses). 
CyclinA2-EGFP expression was no longer evident in cells at telophase (Figure 2B, e2, 
yellow ellipses). This observation was consistent with CyclinA2-EGFP dispersion 
throughout the cytosol during metaphase (Figure 2C, c2) and its absence at late telophase 
(Figure 2C, d2). Altogether, the foregoing indicated that CyclinA2-EGFP was expressed 
from mid-G1 to mid-M phase.
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Quantitative analysis revealed dynamics of CyclinA2 and EdU labeling (Figure 2D and 2E). 
CyclinA2(+)/EdU(−) cells reached a peak at mid-G1 phase, followed by a peak of 
CyclinA2(+)/EdU(+) cells at S phase. At M/G0, CyclinA2(+)/ EdU(−) cells began to 
disappear, whereas CyclinA2(−)/EdU(+) cells began to appear. From foregoing data, as 
schematically diagrammed in Figure 2F, CyclinA2-EGFP appeared somewhat earlier than 
EdU and disappeared at telophase, whereas, as expected, EdU label remained after cell 
division, indicating that CyclinA2-EGFP provided a more sensitive and accurate read-out for 
current cell cycle activity than EdU.
To examine dynamics of CyclinA2-β-galactosidase expression, MEFs were harvested from 
CyclinA2-lacZ-EGFP embryos and used for a time-course experiment, performed as 
described earlier. After fixation, cultures of MEFs were stained with X-gal and 
immunostained with Ser10 anti-phosphohistone 3 antibody, marking G2 to M nuclei,20 and 
DAPI nuclear staining. As observed for CyclinA2-EGFP and as shown in Figure 3A, 
CyclinA2-β-galactosidase was first evident at mid-G1 (Figure 3A, c2) and remained evident 
through S/G2 phase (Figure 3A, d2, e2). At metaphase, CyclinA2-β-galactosidase was 
dispersed throughout the cytosol, (Figure 3A, e2, white circles and Figure 3B, c2; and 
Online Figure II, b2) and was no longer evident in telophase (Online Figure II, c2). 
Therefore, timing of CyclinA2-β-galactosidase expression during cell cycle mirrored that of 
CyclinA2-EGFP.
Next, to further verify that CyclinA2-EGFP expression was not carried over from one cell 
cycle to the next, MEFs were synchronized in G0 by serum starvation, then induced to re-
enter cell cycle by addition of 10% fetal bovine serum. At 24 hours after stimulation (t=0, 
Figure 3D, a1–3), when most cells were in S phase, MEFs were again subjected to serum 
starvation to arrest cell cycle (Figure 3C). At t=0, as expected, all cells expressed CyclinA2-
EGFP (Figure 3D, a2). However, 6 hours after serum withdrawal, most cells had ceased 
CyclinA2-EGFP expression, reflecting entry into late M/G0 (Figure 3D, b1–3), although 
cells in M phase, including early telophase as marked by Serine 28 phosphohistone 3, still 
exhibited faint transgene expression (Figure 3D, b2, white ellipse). At 12 hours after serum 
withdrawal, CyclinA2-EGFP had disappeared completely (Figure 3D, c2, d2). Thus, 
CyclinA2-EGFP had disappeared by late telophase/G0.
To understand cardiac myocyte cell cycle regulation during heart development, CyclinA2-
lacZ-EGFP mice were crossed with a cardiac myocyte–specific Cre mouse line, TnT-Cre.15 
To compare in vivo expression of our cell cycle indicator with EdU labeling, pregnant dams 
were injected intraperitoneally with EdU (30 μg/g; dose per body weight) 2 hours before 
harvest. Embryos were harvested at embryonic day 10.5, 12.5, 14.5, and 18.5, fixed with 4% 
paraformaldehyde, and immunostained with antibodies to GFP, TnT, stained for EdU, and 
with DAPI (Figure 4A).
As expected,13,21,22 at embryonic day 10.5, 12.5, and 14.5, CyclinA2-EGFP was selectively 
expressed in the ventricular compact zone, not in trabeculae. Most CyclinA2-EGFP-positive 
cardiac myocytes overlapped with EdU staining (white arrows). Some CyclinA2-EGFP-
positive cardiac my-ocytes were EdU-negative, as expected, because CyclinA2-EGFP is 
expressed from mid-G1 through M phase, whereas EdU is taken up only by cells undergoing 
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S phase during the EdU pulse. From quantitative analysis, ≈81% of CyclinA2-EGFP-
positive cardiac myocytes were also positive for EdU staining (Online Figure III). As 
expected, EdU staining was also observed in noncardiac myocyte lineages that were not 
stained for TnT. Thus, Cyclin A2-EGFP was expressed in a lineage-specific manner and 
allowed for sensitive detection of cycling cardiac myocytes.
Quantitative analysis of CyclinA2-EGFP expression during examined embryonic stages 
showed that, as previously found,6,21 the proliferation rate of cardiac myocytes gradually 
decreased with progressive development (Figure 4B, left panel). Quantitative analysis 
demonstrated a consistent profile of CyclinA2-EGFP expression and EdU labeling of 
cardiac myocytes, identified by TnT staining (Figure 4B, right panel). Overall, consistency 
of these results with previous studies of embryonic cardiac myocyte proliferation6,13 
validated CyclinA2-EGFP as a cardiac myocyte–specific cell cycle indicator.
At birth, the circulatory system undergoes radical changes, profoundly affecting cardiac 
physiology.23 To examine proliferation of cardiac myocytes perinatally, EdU labeling was 
performed on TnT-Cre;CyclinA2-lacZ-EGFP mice by subcutaneous injection 4 hours before 
harvest. Hearts were harvested at postnatal day 0 (PN0), 1 (PN1), 5 (PN5), and 10 (PN10), 
fixed with 4% paraformaldehyde, sectioned, and immunostained with antibodies to GFP and 
stained for EdU with DAPI nuclear staining (Figure 5A). Identification of myocyte nuclei in 
the context of postnatal heart tissue is challenging.8 Because of the large area comprised by 
individual cardiomyocytes relative to other cardiac cell types, immunostaining for highly 
expressed myocyte cytoskeletal markers, such as TnT, can appear to encompass nuclei that 
are in fact nonmyocyte. Therefore, to identify myocyte nuclei, we used a negative staining 
protocol, using a cocktail of antibodies that comprehensively detected nonmyocyte cell types 
within the heart, including fibroblasts (PDGFRα), endothelial cells (CD31 and CD146), 
blood cells (CD45), and vascular support cells (CD146).24,25 Results of this analysis 
demonstrated that, as expected,6 the number of CyclinA2-EGFP-positive cardiac myocytes 
was reduced between PN0 and PN1 and further reduced by PN10. Intriguingly, during the 
immediate perinatal period (PN0-PN1), we noted fewer cardiac myocytes expressing 
CyclinA2-EGFP in right ventricle relative to left ventricle (LV) or interventricular septum. 
As seen during embryonic stages, from stages examined from PN1 to PN10, most CyclinA2-
EGFP cardiac myocytes exhibited EdU staining. As expected, however, a majority of EdU 
staining at these stages was observed within noncardiac myocyte populations.6
Quantitative analysis of CyclinA2-EGFP and EdU labeling of cardiac myocyte nuclei during 
perinatal stages (Figure 5B) showed expected overall agreement between CyclinA2-EGFP 
and cardiac myocyte EdU labeling. Quantitative analyses confirmed lower rates of cell cycle 
activity of right ventricle cardiac myocytes relative to LV and interventricular septum 
cardiac myocytes at PN0 and PN1 (Figure 5B, right panel).
Binucleation of cardiac myocytes, where they undergo a round of cell cycle with 
karyokinesis but not cytokinesis, occurs from PN4 to PN7,6 suggesting that CyclinA2-EGFP 
expression at PN5 reflected cell cycle activity during binucleation. To address this, PN5 
cardiac myocytes were isolated and plated on glass slides, immunostained with antibodies to 
GFP and sarcomeric-α-actinin, stained for EdU, and with DAPI. Quantitative analysis with 
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isolated cardiac myocytes (n=451) demonstrated that ≈60% of myocytes at this stage were 
mononucleated and ≈35% were binucleated (Figure 6A). Approximately 14% of mono-
nucleated cardiac myocytes expressed CyclinA2-EGFP, whereas only 2% of binucleated 
cardiac myocytes were positive for CyclinA2-EGFP (Figure 6B). The extent of EdU labeling 
of either mononucleated or binucleated cardiac myocytes was again in overall agreement 
with CyclinA2-EGFP expression (Figure 6B). Representative mononucleated and binucle-
ated cardiac myocytes isolated at PN5 are shown (Figure 6C). Together, these results 
indicated that, as expected, CyclinA2-EGFP was expressed during cell cycle events required 
for bi-nucleation, but disappeared after binucleation.
Recent results suggested that a proliferative burst of ventricular cardiac myocytes occurs at 
PN15.26 If this were the case, our CyclinA2-EGFP should be expressed accordingly in 
cardiac myocytes at this stage. To investigate this, and guided by protocols used in the 
previous study,26 EdU (30 μg/g) was injected into TnT-Cre;CyclinA2-lacZ-EGFP mice at 
11:30 am or 9:30 pm on PN14 or 11:30 am on PN15. Hearts were harvested 10.5 hours after 
each EdU injection, at 10 pm on PN14, 8 am on PN15, or 10 pm on PN15. Heart tissue 
sections were immunostained with antibodies to GFP, TnT, and stained for EdU, and with 
DAPI. Extremely rare Cyclin A2-EGFP cardiac myocytes were observed, some of which 
were also positive for EdU label (Figure 7A). As expected, the majority of EdU-positive 
cells were labeled by the cocktail of antibodies to noncardiac myocyte markers (Figure 7B, 
blue circles). Quantitative analysis revealed that the number of CyclinA2-EGFP-positive 
cells per total cardiac myocytes gradually decreased in the range from 0.025% to 0.010% 
throughout PN14 and PN15 (Figure 7C). These numbers are consistent with quantitative 
analysis of cardiac myocyte proliferation rates in young adult mice using stable isotope 
labeling.27 We further investigated rates of cardiac myocyte cell cycle activity from PN14 to 
PN20 by quantification of CyclinA2-EGFP- and EdU-labeled cells. As shown in Online 
Figure IV, rates of cardiac myocyte cell cycle activity gradually and steadily decreased from 
PN14 throughout PN20.
To ensure that CyclinA2-lacZ-EGFP transgenes could be expressed at this stage, EdU 
labeling of Protamine-Cre;CyclinA2-EGFP mice was performed by peritoneal injection 6 
hours before harvest, and hearts were harvested at PN15. CyclinA2-EGFP-positive cells that 
colocalized with EdU staining were observed within the LV wall at PN15 (Online Figure 
VA). Sections of PN15 hearts from CyclinA2-lacZ-EGFP mice were also stained for X-gal. 
CyclinA2-β-galactosidase cells were observed scattered throughout the heart (Online Figure 
VB). Thus, CyclinA2-LacZ and -EGFP transgenes could be expressed at these stages.
Discussion
In summary, we have generated a CyclinA2-EGFP transgene that reports cell cycle activity 
in a Cre-dependent manner, providing sensitive readout of cell cycle activity in cardiac 
myocytes or other cell types of interest. One advantage of our indicator relative to recently 
described tissue-specific FUCCI (fluorescent ubiquitination-based cell cycle indicator) 
indicators11,12 is that our indicator relies on a single fluorescence marker to report cell cycle 
activity, leaving other fluorescence channels available for additional markers. CyclinA2-
EGFP was expressed from mid-G1 to mid-M phase, similar to endogenous cyclinA2,14,28 
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although slightly earlier and later, perhaps owing to enhanced sensitivity of detection or 
transgene stability. Using TnT-Cre, we compared cardiac myocyte–specific expression of 
CyclinA2-EGFP to results with EdU labeling. Owing to tissue complexity, attribution of 
cardiac myocyte–specific EdU staining is extremely challenging.8 In contrast, CyclinA2-
EGFP provided a robust and sensitive readout of cardiac myocytes actively engaged in cell 
cycle activity. Additionally, the CyclinA2-EGFP reporter indicates cells that are actively 
engaged in cell cycle at the time of harvest, whereas EdU label can also be present in cells 
that have exited cell cycle. Another potential advantage to our reporters is that nucleosides 
and nucleoside analogs like thymidine and EdU are also incorporated during DNA repair 
consequent to DNA damage, whereas CyclinA2 is activated during bona fide cell cycle 
activity. This issue may be of particular relevance in the perinatal period, where cardiac 
myocytes exhibit increased DNA damage in response to increased oxidative stress, 
promoting cell cycle withdrawal.29
Using CyclinA2-EGFP, we discovered that rates of cell cycle activity in right ventricular 
cardiac myocytes at P0 and P1 were reduced relative to those of LV cardiac myocytes. This 
differential rate of cardiac myocyte cell cycle activity might, at least in part, contribute to 
differences in size between postnatal right ventricle and LV and may reflect relative 
increased pressures experienced by the LV and interventricular septum after birth.23
Utilization of the cardiac myocyte–specific cell cycle indicator allowed us to re-examine 
recent findings of a burst of myocyte cell cycle re-entry at PN15.26 Examination of 
CyclinA2-EGFP expression consequent to TnT-Cre activity, in concert with EdU labeling, 
demonstrated that cardiac myocytes do not exhibit a burst of proliferative activity at PN15. 
These findings serve to illustrate the challenges of attributing observed cell cycle activity to 
cardiac myocytes within complex cardiac tissue in the absence of a clear myocyte-specific 
indicator, as now provided by this new cell-specific cell cycle reporter. We also describe the 
development of a complementary method to negatively define cardiac myocyte nuclei by 
utilization of a cocktail of antibodies that comprehensively marks nonmyocyte populations 
within the heart.
In this report, we have focused on the utility of our reporter for studying cardiac myocyte 
cell cycle activity. It should be noted that the CyclinA2-lacZ-EGFP transgene will also have 
great utility in the context of other cell types during development and in the adult and in the 
context of both regenerative medicine and cancer.
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• Understanding and promoting postnatal cardiac myocyte cell cycle regulation 
is a major goal of regenerative therapies for heart disease.
• Studies of myocyte proliferation in postnatal heart are challenging owing to 
tissue complexity.
What New Information Does This Article Contribute?
• We characterize a novel cell-type–specific cell-cycle reporter and use it to 
examine cardiac myocyte proliferation.
• We found reduced proliferation of right ventricular cardiac myocytes relative 
to left ventricular cardiac myocytes in perinatal period.
• In contrast to a recent study, there was no proliferative burst of cardiac 
myocytes at postnatal day (PN) 14 or PN15.
We have developed a new transgenic mouse line that enables visualization of cell cycle 
activity in specific cell types, including cardiac myocytes, consequent to Cre activity. 
Characterization of CyclinA2-floxed:LacZ-GFP mice demonstrated excellent agreement 
between pulse EdU labeling and CyclinA2-reporter expression. CyclinA2-fusion 
reporters were expressed from mid-G1 to late-M phase. Unexpectedly, studies using the 
Troponin T-Cre;CyclinA2-floxed:LacZ-GFP mice revealed reduced proliferation of right 
ventricular cardiac myocytes relative to left ventricular cardiac myocytes in the perinatal 
period. In contrast to a recent study, studies with Troponin T-Cre;CyclinA2-floxed;LacZ-
GFP mice showed no proliferative burst of cardiac myocytes at PN14 or PN15. 
CyclinA2-floxed;LacZ-GFP reporter mice can be used to selectively visualize 
proliferating cardiac myocytes during embryonic development and in the postnatal 
period, addressing a current limitation in the field.
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Figure 1. A, Diagram of CyclinA2 indicator bacterial artificial chromosome (BAC) transgene
A floxed lacZ cassette and an enhanced green fluorescent protein (EGFP) cassette were 
inserted in frame immediately before the cyclinA2 stop codon. B, CyclinA2-LacZ will be 
expressed under control of cyclinA2 sequences on the BAC. TnT-Cre;CyclinA2-LacZ-EGFP 
mice express CyclinA2-EGFP selectively in cardiac myocytes. C, Southern blot confirming 
transgene integration.
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A, Diagram of time-course experiment shown in B. B, Time-course experiment after 
synchronization of CyclinA2-enhanced green fluorescent protein (EGFP) mouse embryonic 
fibroblasts (MEFs). Cells were immunostained with antibodies to green fluorescent protein 
(GFP), Serine 28 phosphohistone 3 (S28pH3), and stained for 5-ethynyl-2′-deoxyuridine 
(EdU) and with DAPI. Scale bar: 100 μm. C, Fluorescence microscope images of CyclinA2-
EGFP MEFs in mid G1 (a1–4), S (b1–4), metaphase (c1–4), and telophase (d1–4). Note 
cytosolic dispersion of CyclinA2-EGFP in metaphase (c2) and its disappearance in telophase 
(d2). Scale bar: 50 μm. D, Quantitative analysis of CyclinA2-EGFP or EdU-positive cells at 
each time point. E, Quantitative analysis of CyclinA2-EGFP/EdU double- or single-positive 
cells at each time point. F, Schematic diagram of CyclinA2-EGFP expression and EdU 
incorporation throughout cell cycle.
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Figure 3. A, Time-course experiment after synchronization of CyclinA2-LacZ-enhanced green 
fluorescent protein (EGFP) mouse embryonic fibroblasts (MEFs)
MEFs were stained with X-gal, followed by immunostaining with anti-Serine10 
phosphohistone 3 antibody (S10pH3) and staining with DAPI. Cells begin to express 
CyclinA2-βgal at mid G1 (c2). Scale bar: 50 μm. B, Images of CyclinA2-LacZ-EGFP MEFs 
at G0 (a1–3), S (b1–3), and M phase (c1–3). Cells were stained with X-gal, followed by 
immunostaining for S10pH3 and staining with DAPI. CyclinA2-β-galactosidase (β-gal) was 
expressed during S phase (b2) and dispersed within cytosol at M phase (c2). C, Diagram of 
time-course experiment shown in D. D, Time-course experiment after serum starvation of 
CyclinA2-EGFP MEFs. MEF cells were stained for CyclinA2-EGFP, S28pH3, and DAPI. 
CyclinA2-EGFP disappeared at telophase after serum starvation (b1–3, white circles), then 
completely disappeared (c1–3, d1–3). Scale bar: 100 μm.
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Figure 4. A, Fluorescence microscopy of embryonic day (ED) 10.5, ED12.5, ED14.5, and ED18.5 
heart sections of Troponin T (TnT)-Cre;CyclinA2-LacZ-EGFP mice
Sections were immunostained for CyclinA2-EGFP and Troponin T and stained for 5-
ethynyl-2′-deoxyuridine (EdU) and with DAPI. CyclinA2-EGFP expression was largely 
confined to the compact layer. CyclinA2-EGFP/EdU double-positive cells are indicated by 
white arrows. For lower magnification (upper three panels), scale bar denotes 50 μm; for 
higher magnification images (lower panel), scale bar denotes 20 μm. B, Quantitative 
analysis of CyclinA2-EGFP and EdU-positive myocardial cells at ED10.5, ED12.5, ED14.5, 
and ED18.5. Myocardial cells were defined by Troponin T staining. Note gradual and steady 
decrease of CyclinA2-EGFP- and EdU-positive myocardial cells. Cmpt indicates compact 
layer; and Trbc, trabecula.
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Figure 5. A, Fluorescence microscopy of heart sections from postnatal day 0 (PN0), day 1 (PN1), 
day 5 (PN5), and day 10 (PN10) TnT-Cre;CyclinA2-LacZ-EGFP mice
Sections were immunostained with antibodies for CyclinA2-EGFP, a cocktail of antibodies 
to PDGFRα, CD31, CD45, and CD146 stained for 5-ethynyl-2′-deoxyuridine (EdU) and 
DAPI. Images of left ventricle (LV), right ventricle (RV), and interventricular septum (IVS) 
are shown. CyclinA2-EGFP/EdU double-positive cells are indicated by white arrows. Note 
reduced number of CyclinA2-EGFP- or EdU-positive cardiac myocyte nuclei in RV relative 
to LV or IVS at PN0 and PN1. Scale bar: 50 μm. B, Quantitative analysis of CyclinA2-
EGFP- and EdU-positive myocardial nuclei at PN0, PN1, PN5, and PN10. Myocardial cells 
were defined by excluding nonmyocardial cells labeled with either PDGFRα, CD31, CD45, 
or CD146. Note that all CyclinA2(−)/EdU(+) cells were labeled with either PDGFRα, 
CD31, CD45, or CD146.
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Figure 6. A, Quantitative analysis of the fraction of mononucleated and binucleated cardiac 
myocytes from PN5 TnT-Cre;CyclinA2-LacZ-enhanced green fluorescent protein (EGFP) hearts
A total of 451 cardiac myocytes were subjected to quantification. B, Quantitative analysis of 
the percentage of mononucleated or binucleated cardiac myocytes that were positive for 
CyclinA2-EGFP or 5-ethynyl-2′-deoxyuridine (EdU). C, Fluorescence microscopy of 
cardiac myocytes isolated from PN5 TnT-Cre;CyclinA2-LacZ-EGFP hearts. Cells were 
immunostained for CyclinA2-EGFP, sarcomeric-α–actinin, stained for EdU and DAPI. 
Scale bars: 20 μm.
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Figure 7. A, Fluorescence microscopy of heart sections from TnT-Cre;CyclinA2-LacZ-enhanced 
green fluorescent protein (EGFP) mice at PN14 and PN15 stained for CyclinA2-EGFP, Troponin 
T, 5-ethynyl-2′-deoxyuridine (EdU), and DAPI
Mice were labeled with EdU during indicated time frames. CyclinA2-EGFP-positive cells 
were extremely rare. A single CyclinA2-EGFP-positive cardiac myocyte in the field is 
shown (white circle). CyclinA2-EGFP-positive but EdU-negative cardiac myocytes were 
also observed. Scale bar: 50 μm. B, Fluorescence microscopy of heart sections from TnT-
Cre;CyclinA2-LacZ-EGFP mice at PN14 stained for CyclinA2-EGFP, PDGFRα, CD31, 
CD45, CD146, EdU, and DAPI. All EdU-positive/ CyclinA2-EGFP-negative cells were 
labeled with either anti-PDGFRα, anti-CD31, anti-CD45, or anti-CD146 antibody (blue 
circles). Scale bar: 50 μm. C, Quantitative analysis of CyclinA2-EGFP myocardial cells 
throughout PN14 and PN15. Note gradual and steady decrease.
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